An interventional study of LIBERTY Patch and Sham Patch in Fall Risk, Fall Risk, Fall Prevention and Accidental Falls, sponsored by SuperPatch Limited LLC. Enrolling by invitation at 1 site in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by SuperPatch Limited LLC · Not applicable, Interventional, and Prevention
This study evaluates whether a drug-free, non-invasive haptic patch (LIBERTY Patch) affects fall-risk classification and balance/mobility confidence in adults ages 55 to 85. Approximately 150 participants are assigned to wear either the active LIBERTY Patch or a visually identical sham patch daily for 7 days. Balance and mobility are assessed using the FallSkip wearable device and a Falls Efficacy Scale questionnaire at baseline and again after 7 days. Neither participants nor investigators know which patch is assigned during the study period, though this can be unblinded in an emergency.
The PROTECT Study is designed to classify participants into fall-risk categories and evaluate whether use of the LIBERTY Patch, a drug-free, non-invasive, investigational device employing Haptic Vibrotactile Trigger Technology, is associated with a change in fall-risk category or balance/mobility confidence relative to a sham (inactive) patch control.
After informed consent, participants complete a Baseline Survey (including the Falls Efficacy Scale, a 10-item instrument adapted from Tinetti et al., 1990, assessing confidence in performing daily activities without falling) and undergo a brief (2-3 minute) walking and mobility assessment using the FallSkip wearable device, worn at the waist, involving sitting, standing, walking several feet, and returning to a seated position. Participants are then given a study patch - either the active LIBERTY Patch or a visually identical sham patch - to wear daily. After 7 days, participants repeat the FallSkip mobility assessment and complete a Follow-Up Survey, which re-administers the Falls Efficacy Scale and adds items on patch satisfaction, ease of use, convenience, and any side effects experienced (hot/cold sensation, massage/tingling sensation, pressure sensation, or none). Neither the participant nor the investigator is informed of patch assignment during the study period, though the investigator can unblind in case of emergency. After the 7-day period, participants may optionally continue in the study using the alternate patch.
Exclusion Criteria:
Participants apply the active LIBERTY Patch (Haptic Vibrotactile Trigger Technology) daily for 7 days, with fall-risk/mobility assessment (FallSkip device) and Falls Efficacy Scale survey completed at baseline and Day 7.
Device: LIBERTY Patch
Participants apply a visually identical sham patch without active technology daily for 7 days, with the same baseline and Day 7 assessments as the Active arm.
Device: Sham Patch
A drug-free, non-invasive, investigational topical patch designed to assist with balance and mobility, worn daily for 7 days.
Also known as: Haptic Vibrotactile Trigger Technology (VTT) Patch
A visually identical patch without active technology, worn daily for 7 days under the same conditions as the active patch.
Change in fall-risk/mobility assessment (FallSkip device)
A 2-3 minute mobility assessment (sit-to-stand, walking, and return to seated position) using the FallSkip wearable device, comparing Active vs. Control groups.
Time frame: Baseline and Day 7
Change in Falls Efficacy Scale score
A 10-item, self-reported scale (adapted from Tinetti et al., 1990) measuring confidence in performing daily activities (bathing, dressing, walking, transferring, etc.) without falling, scored 1 (very confident) to 10 (not confident at all) per item.
Time frame: Baseline and Day 7
Incidence of patch-associated sensations/side effects
Self-reported occurrence of hot/cold sensation, massage/tingling sensation, pressure sensation, or none, associated with patch use.
Time frame: Throughout the 7-day study period, assessed at Day 7
Plan to share: No — Individual participant data will not be shared. This is a minimal-additional-risk, single-site-network study in an at-risk elderly population (ages 55-85) evaluating an investigational, non-significant-risk device, conducted under a HIPAA Authorization and Advarra IRB oversight. Participant health data are used and disclosed only to the parties specified in the informed consent (the sponsor, Clarity Science, LLC, Advarra IRB, and applicable regulatory authorities) for purposes of conducting this study. Given the population's potential vulnerability (older adults, some with mobility impairment) and the narrow consented scope of data use, de-identified data sharing beyond these parties was not part of the consent framework, consistent with the study's HIPAA Authorization.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SuperPatch Limited LLC